

CORRECTION

Open Access



# Correction to: Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma

Xiaobin Wu<sup>1†</sup>, Runkun Han<sup>2†</sup>, Yanping Zhong<sup>3</sup>, Nuoqing Weng<sup>1\*</sup> and Ao Zhang<sup>2\*</sup> 

## Correction to: *Cancer Cell Int* (2021) 21:356

<https://doi.org/10.1186/s12935-021-02072-x>

In this article [1], the author name “Xiaobin Wu” was incorrectly written as “Xianbin Wu”. This has been corrected in this correction.

In addition, there was a printing mistake in Table 7. The correct information of 1714 is 14, 1417 is 17, 5350 is 50 and 6669 is 69. The corrected Table 7 is given below.

**Table 7** Changes of NLR in patients of response and non-response groups

Group	Trend		
	Decrease	Increase	Total
Response	36	52	88
Non-response	14	17	31
Total	50	69	119
P value	0,679		

The original article can be found online at <https://doi.org/10.1186/s12935-021-02072-x>.

\*Correspondence: [wengnq3@mail.sysu.edu.cn](mailto:wengnq3@mail.sysu.edu.cn); [zhangao@sysucc.org.cn](mailto:zhangao@sysucc.org.cn)

<sup>†</sup>Xiaobin Wu and Runkun Han contributed equally to this work

<sup>1</sup>Department of Gastrointestinal Surgery, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China

<sup>2</sup>Department of Laboratory Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China

Full list of author information is available at the end of the article

## Author details

<sup>1</sup>Department of Gastrointestinal Surgery, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China. <sup>2</sup>Department of Laboratory Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. <sup>3</sup>Department of Health Management, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.

Accepted: 9 December 2021

Published online: 20 December 2021

## Reference

1. Wu X, Han R, Zhong Y, Weng N, Zhang A. Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma. *Cancer Cell Int.* 2021;21:356. <https://doi.org/10.1186/s12935-021-02072-x>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.